What are the mechanisms of action and therapeutic uses of amantadine?

Amantadine — What it does

Amantadine blocks influenza A M2 ion-channel activity and weakly antagonizes NMDA receptors; clinically, use it for influenza A prophylaxis/treatment (where appropriate and early) and for Parkinson’s disease/drug-induced extrapyramidal symptoms to improve motor function and, in select neuro patients, arousal/behavior. 1, 2, 3

Mechanisms of action (most clinically relevant)

• Antiviral (Influenza A):
  • Inhibits M2 proton channel → prevents viral uncoating and may impair assembly/release; active only against influenza A, not B 1.
• Neuro:
  • Weak, non-competitive NMDA receptor antagonism; dopaminergic modulation likely contributes to antiparkinsonian effects; anticholinergic-like side effects occur clinically 1.

Therapeutic uses (prioritize morbidity, mortality, QOL)

• Influenza A
  • Chemoprophylaxis and early treatment reduce illness severity/duration; start within 48 hours when circulating influenza A is suspected/confirmed. Note: resistant strains can emerge; stop when clinically warranted (3–5 days) to limit resistance and adverse effects 3.
  • Not effective for influenza B 1.
• Parkinson’s disease and drug-induced extrapyramidal reactions
  • Improves motor symptoms; NMDA antagonism and dopaminergic effects underlie benefit, supporting QOL gains in tremor, rigidity, and dyskinesias 1.
• Brain injury/neurostimulation (adjunct, off-label)
  • May improve wakefulness/behavior (irritability/aggression); evidence mixed and not definitive for mortality but can aid QOL in selected patients; use after weighing renal function and CNS risks 4, 5. Prioritize approved indications first.

How to use (concise algorithm)

1. Identify indication:
   • Influenza A prophylaxis/treatment during active A circulation and within 48 h of symptom onset; avoid for B 3, 1.
   • Parkinson’s disease or antipsychotic-induced EPS 1.
2. Dose and duration:
   • Typical adult total 200 mg/day; reduce to ≤100 mg/day in elderly or renal impairment to minimize CNS toxicity while preserving antiviral prophylaxis efficacy 3, 6.
   • Influenza treatment: generally 3–5 days; stop once clinically warranted to reduce resistance 3.
3. Safety checks (avoid morbidity):
   • Renal function: mandatory dose reduction; drug is renally cleared; hemodialysis minimally clears it 6, 7.
   • CNS risk: elderly, seizure disorders, psychiatric illness → higher risk of confusion, hallucinations, seizures; lower dose mitigates risk 2.
   • Anticholinergic cautions: avoid in untreated angle-closure glaucoma 2.
4. Resistance and infection control:
   • Amantadine-resistant influenza A can emerge and transmit; separate treated ill patients from those on prophylaxis in institutions; report resistant isolates per public health guidance 3.

Common pitfalls and how to avoid them

• Using for influenza B or starting influenza treatment after >48 h → limited/no benefit; avoid 3, 1.
• Not reducing dose in renal impairment/elderly → increases CNS toxicity and harms QOL; reduce to ≤100 mg/day and monitor 3, 6.
• Prolonging antiviral therapy unnecessarily → fosters resistance; stop within 3–5 days when improved 3.
• Overlooking glaucoma risk (mydriasis) → avoid in untreated angle-closure glaucoma 2.

Evidence notes

• Highest-quality, most recent authoritative source for mechanisms/indications is the FDA label (2026) supporting M2 inhibition and NMDA antagonism, and indications in influenza A and Parkinson’s/EPS 1.
• ACIP guidelines consistently endorse amantadine for influenza A prophylaxis/treatment with safety and dosing caveats; they emphasize early use, resistance management, and renal dosing to protect morbidity and QOL 2, 3.